Rani Therapeutics Scheduled to Announce Q3 2026 Financial Results
Rani Therapeutics Holdings, Inc. is scheduled to release its financial results for the third quarter of 2026 on November 5, 2026.
Stocks · News reference
This Definium Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Top analysts changed outlook on top names. See analyst ratings page for all changes.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
B. Riley Adjusts Price Target on Ramaco Resources to $17
B. Riley has lowered its price target for Ramaco Resources, Inc. from $24 to $17 while maintaining a "Buy" rating.
Sunshine Silver Mining & Refining Completes 50,000-Meter Infill Drill Program
Sunshine Silver Mining & Refining Company has finished its 50,000-meter infill drilling program at the Sunshine Mine in Idaho, reporting high-grade silver results.
8-K filing — Sunshine Silver Mining & Refining Co (SSMR)
Filed: 2026-11-05 AccNo: 0001628280-26-070509 Size: 10 MB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Definium Therapeutics Presents Topline Phase 3 Data for DT120 ODT at 2026 NEI Fall Congress
Definium Therapeutics announced the presentation of positive topline Phase 3 data for its lead candidate, DT120 ODT, at the 2026 NEI Fall Congress.
Ramaco Resources Reports Third Quarter 2026 Results
Ramaco Resources, Inc. announced its financial results for the third quarter ended September 30, 2026, reporting a quarterly net loss of $18.2 million.